At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 235 enrolled
Drug / intervention
TD-0903 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, Multi-center Study of an Inhaled Pan-Janus Kinase Inhibitor, TD-0903, to Treat Symptomatic Acute Lung Injury Associated With COVID-19
In Brief
A Phase 2 clinical trial evaluating TD-0903 and Placebo for Acute Lung Injury (ALI) Associated With COVID-19 and Lung Inflammation Associated With COVID-19. Completed, enrolled 235 participants across 24 sites in 7 countries.
Detailed Summary
This Phase 2 study will evaluate the efficacy, safety, pharmacodynamics and pharmacokinetics of inhaled TD-0903 compared with a matching placebo in combination with standard of care (SOC) in hospitalized patients with confirmed COVID-19 associated acute lung injury and impaired oxygenation.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Lung Injury (ALI) Associated With COVID-19, Lung Inflammation Associated With COVID-19
CountriesBrazil, Finland, Moldova, Romania, Ukraine, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedMay 2020
Enrollment StartJun 2020
Primary CompletionApr 2021
TodayJul 2026
First PostedMay 27, 2020
Enrollment StartJun 24, 2020
Primary CompletionApr 21, 2021
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 6.1 years ago
Interventions
TD-0903drug
Study Drug to be administered by inhalation
Placebodrug
Placebo to be administered by inhalation